![“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said Thaddeus Beck, MD, FACP.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/cbb0bc385f194a5dd84702ed02a21020e3a6977b-1200x1800.jpg?w=350&fit=crop&auto=format)
“We want to make sure we are not producing a financial burden for patients in exchange for that convenience [with subcutaneous therapies],” said Thaddeus Beck, MD, FACP.
|Articles|March 1, 1995
Oncology NEWS International
- Oncology NEWS International Vol 4 No 3
- Volume 4
- Issue 3
Coram to Purchase Caremark's Home Infusion Therapy Business
DENVER--Coram Healthcare Corp. has reached a definitive agreement to acquire Caremark International's home infusion therapy business. Under the agreement, Caremark will receive approximately $310 million in cash and securities.
Advertisement
DENVER--Coram Healthcare Corp. has reached a definitive agreementto acquire Caremark International's home infusion therapy business.Under the agreement, Caremark will receive approximately $310million in cash and securities.
Articles in this issue
over 31 years ago
Selecting a Support Group for Patients With Prostate Carcinomaover 31 years ago
Antman Provides Outlook on Use of High-Dose Chemoover 31 years ago
Radiofrequency Ablation of Brain Tumors New Optionover 31 years ago
Oncologist Enthusiastic About Capitated Planover 31 years ago
Varmins Chooses New Director for NIH Office of Alternative Medicineover 31 years ago
'Visible Man' Hits the Internet, Radiologists Get the First Lookover 31 years ago
Ultrafast Full-Body MRI Eases Procedure in Claustrophobics, KidsAdvertisement
Related to this article
Nitin Ohri, MD, MS, explains the rationale for combining thoracic radiotherapy with dual PD-1 and LAG-3 blockade in locally advanced NSCLC.
At the 2026 ASTRO Annual Meeting, Marcio A. Fagundes, MD, discussed when proton therapy is most justified over photon approaches in prostate cancer.
Ayal Aizer, MD, MHS, discussed Alliance A071801 data favoring fractionated SRS over single-fraction SRS after brain metastasis resection.
Marcio A. Fagundes, MD, explained how proton therapy and rectal spacers can reduce radiation exposure to the rectum, bowel, and bladder in prostate cancer.
Bruce Haffty, MD, and Mutlay Sayan, MD, on building radiation oncology at Rutgers, the future of the field, and a remarkable journey from eastern Turkey to Harvard faculty.
Marcio A. Fagundes, MD, discussed disease control by risk group among 404 patients with prostate cancer treated with intensity-modulated proton therapy.
The approval expands the indication of pirtobrutinib to patients with previously untreated chronic lymphocytic leukemia/small lymphocytic lymphoma with no known 17p deletion.
Advertisement
Advertisement
Trending on CancerNetwork
1
Prioritizing Proton Therapy for Pelvic Nodal Irradiation in Prostate Cancer
2
EXCALIBER-RRMM: Iberdomide in Relapsed/Refractory Multiple Myeloma
3
FDA OKs Pirtobrutinib in Frontline CLL/SLL
4
Alliance A071801 Supports Fractionated SRS After Brain Metastasis Surgery
5